---

---

tags : Test    symbols : LMDX   

save search

---

LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
Published: 2023-06-30 (Crawled : 18:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M |

| Email alert Add to watchlist
fda covid test application

---

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
Published: 2023-01-31 (Crawled : 22:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M |

| -98.31% | O: -0.5% H: 4.24% C: 4.24%
care test commercial health heart

---

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test LumiraDx Limited, a next-generation point of care diagnostics company, announced it has receiv...
Published: 2022-12-14 (Crawled : 10:00) - biospace.com/
RLFTF | $1.45 11.45% 1.3K |

n/a

| 4865.75% | O: -10.62% H: 18.77% C: 5.75%
LMDX | $0.016 -15.0% 130M |

| -98.37% | O: -2.04% H: 6.22% C: -4.9%
care ongoing test diagnostics molecular

---

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
Published: 2022-12-14 (Crawled : 09:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M |

| -98.37% | O: -2.04% H: 6.22% C: -4.9%
care ongoing test molecular

---

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Published: 2022-11-14 (Crawled : 08:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M |

| -98.49% | O: -0.94% H: 15.24% C: 4.76%
expansion test commercial rapid

---

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
Published: 2022-06-09 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.63% | O: -1.87% H: 0.0% C: -6.67%
covid-19 system test

---

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
Published: 2022-06-02 (Crawled : 11:00) - prnewswire.com
LMDX | $0.016 -15.0% 130M |

| -99.54% | O: 1.42% H: 10.11% C: -2.81%
test cardiovascular

---

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
Published: 2022-05-26 (Crawled : 10:00) - prnewswire.com
LMDX | $0.016 -15.0% 130M |

| -99.57% | O: 0.81% H: 6.67% C: 4.8%
care test growing diagnostic diabetes platform

---

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
Published: 2022-05-20 (Crawled : 10:00) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.59% | O: -2.81% H: 3.95% C: 1.84%
test sars-cov-2

---

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Published: 2022-01-14 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.83% | O: 0.0% H: 2.78% C: 1.95%
covid-19 covid test

---

LumiraDx CRP Test Achieves CE Marking
Published: 2022-01-11 (Crawled : 12:30) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.82% | O: -1.95% H: 4.91% C: 2.92%
test

---

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Published: 2021-12-23 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.82% | O: 0.77% H: 3.92% C: -2.18%
covid-19 ce mark covid test

---

Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.82% | O: 2.97% H: 3.74% C: -2.67%
fda covid authorization test merge covid-19 emergency use authorization

---

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.83% | O: 8.54% H: 3.01% C: -7.67%
fda test molecular sars-cov-2

---

LumiraDx receives approval for its COVID-19 Antigen Test for use in India
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
LMDX | $0.016 -15.0% 130M |

| -99.81% | O: 20.4% H: 3.25% C: -6.7%
covid test india approval covid-19

---

Gainers vs Losers

73%

27%

Top 10 Gainers

MTTR | News M | $4.8 175.86% 63.6% 71M |

AGBA | $2.5 100.0% 56.6% 200M |

Finance

MLEC | $2.47 76.43% 42.62% 78M |

n/a

NUWE | $0.334 29.96% 40.99% 2.5M |

Manufacturing

EDBL | News | $6.26 66.49% 40.13% 16M |

ATGL | $2.86 46.25% 32.8% 180K |

ONFO | $0.6088 38.68% 27.74% 7.3M |

n/a

VIVK | $1.43 33.65% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.7M |

SDIG A | $3.64 35.32% 26.0% 990K |

---

Your saved searches

---